Primary B cell immunodeficiencies: comparisons and contrasts
about
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cellsThe kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophilsToll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responsesThe Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyTargeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinibThe Production Processes and Biological Effects of Intravenous ImmunoglobulinIbrutinib (PCI-32765) in chronic lymphocytic leukemiaGenetics of SCIDHuman genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathwayTargeting Btk/Etk of prostate cancer cells by a novel dual inhibitorDifferential gene expression analysis by RNA-seq reveals the importance of actin cytoskeletal proteins in erythroleukemia cells.Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibitionPhysiological IgM class catalytic antibodies selective for transthyretin amyloid.IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency.The many faces of common variable immunodeficiency.Complex phosphorylation dynamics control the composition of the Syk interactome in B cells.B cell TLRs and induction of immunoglobulin class-switch DNA recombination.Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.Activation of Ras overcomes B-cell tolerance to promote differentiation of autoreactive B cells and production of autoantibodiesThe Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.The pre-B cell receptor checkpoint.Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia modelA custom 148 gene-based resequencing chip and the SNP explorer software: new tools to study antibody deficiency.Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis.Morbidity and mortality in common variable immune deficiency over 4 decadesB-cell subpopulations in children: National reference valuesInhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.Relevance of laboratory testing for the diagnosis of primary immunodeficiencies: a review of case-based examples of selected immunodeficiencies.Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease.Atypical X-linked agammaglobulinaemia caused by a novel BTK mutation in a selective immunoglobulin M deficiency patient.Splice-correction strategies for treatment of X-linked agammaglobulinemia.Proteomic changes during B cell maturation: 2D-DIGE approach.Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100.Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.Btk29A-mediated tyrosine phosphorylation of armadillo/β-catenin promotes ring canal growth in Drosophila oogenesis.Novel sequencing-based strategies for high-throughput discovery of genetic mutations underlying inherited antibody deficiency disordersEnhancer-promoter communication and transcriptional regulation of Igh
P2860
Q21195261-CC66C2BE-433A-43D5-9186-AFF08A69D3CEQ24306260-C571A666-316C-485E-ABAA-7BF84BB1CA6CQ24624348-7FAA3A26-CC0A-4E4C-BC3B-B97D28C77F47Q24633214-E9C38884-5C1D-411E-8DA4-A48A13347191Q26744277-C90CD960-1932-4944-B673-BF1330845441Q26752540-C516499F-8FA2-4FA0-8C37-14C0AA8CBADEQ26852328-6E33BDE4-76D8-4034-84F9-95A6ECC6ED1EQ27499229-8E3F44DC-EA6F-4D7B-9B7D-7A8E2DB88005Q28488150-D8DF5C46-1B43-4CB8-BAD8-672940F8450CQ30661625-060B536B-A619-41A0-9A09-FBC9ACBB89AAQ32186337-1C88FECF-22DB-4AED-A441-E65D2EDF659AQ33566063-441BD4D4-6A0C-4C55-A9FB-795A8AB5625EQ33676625-E9CC1818-492C-4B2C-814F-68CAEB39EC5BQ33707455-0A2623BF-8887-49C9-8F28-12F1C9A68BF2Q33755327-F9F32F98-A463-4254-BC17-EFA2967961ECQ33790739-DC765542-9126-4D6E-A47A-389894128CA4Q33863904-295F41ED-3E7D-4CBB-9472-9307DC7566C9Q33893517-E26D80EB-E06B-45F9-ADB3-4081E3FB1A33Q33893704-74267861-CC15-4AE6-98FE-D08E40323655Q33919653-D9D94AA9-B5B9-450B-9D1F-E121833C9410Q34029869-82F95CE2-3539-420B-B050-35FB22A7F74AQ34039406-18963F7F-A43F-4A8C-A642-AB9EA7B8282DQ34041311-678DCBD2-2352-4276-A193-4956301D7218Q34112228-6D56DA09-D143-44C6-AF6C-B16E63682C37Q34117470-FB192E99-1B2B-4472-AC97-1C17144CD4C2Q34155993-B6B16C90-450F-4C97-AA07-EA67E7822448Q34158815-08B387D6-4B45-49D6-91BD-89BD63AC8C65Q34241472-D8E92FEB-1614-442F-9BB0-59FCD9157104Q34641142-88420DD5-3953-4577-B112-BB697E28874EQ34722000-13B2E613-300D-472D-8930-98C5CBA94150Q34832611-63A770F7-18BF-4BBC-AB14-C9C868473A83Q34992223-158AAEDF-54A9-4259-B590-A3CBF7C4ADA3Q35001259-0D2FD237-7093-4124-B596-D9DA04AA7345Q35033817-EB435F13-D39E-4B2A-9ED0-0AE54C6D82D0Q35035757-1DA60BE6-D044-440F-8BED-4891D8954A1FQ35062895-B84C81B3-571E-490C-A56A-C24E3465FC5CQ35164284-A55C253B-A2A6-46ED-BD62-3F855952446FQ35214149-4332F01A-680C-4951-90C5-CB72B36B5FC0Q35231715-5D22EF33-10FD-4FD7-89E3-E7196CDC1628Q35435000-F92BA15F-1C78-4E6D-B9F1-CD5DEBB0FFDF
P2860
Primary B cell immunodeficiencies: comparisons and contrasts
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Primary B cell immunodeficiencies: comparisons and contrasts
@en
Primary B cell immunodeficiencies: comparisons and contrasts.
@nl
type
label
Primary B cell immunodeficiencies: comparisons and contrasts
@en
Primary B cell immunodeficiencies: comparisons and contrasts.
@nl
prefLabel
Primary B cell immunodeficiencies: comparisons and contrasts
@en
Primary B cell immunodeficiencies: comparisons and contrasts.
@nl
P2093
P1476
Primary B cell immunodeficiencies: comparisons and contrasts.
@en
P2093
A Kerry Dobbs
Dana M Farmer
Dario Campana
Elaine Coustan-Smith
Kenneth Paris
Sebnem Kilic
Sofia Grigoriadou
Vanessa Howard
P304
P356
10.1146/ANNUREV.IMMUNOL.021908.132649
P577
2009-01-01T00:00:00Z